Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: J Neurochem. 2008 Sep 18;107(2):557–569. doi: 10.1111/j.1471-4159.2008.05633.x

Figure 6.

Figure 6

LPS enhanced IL-6 expression and release in primary microglia and BV-2 cells. Primary microglia, BV-2 or HAPI cells were treated with 0, 5 ng/ml, 50 ng/ml, 1 μg/ml or 5 μg/ml LPS for 24 h or 0, 1 or 5 μg/ml LPS for 48 h. (a) LPS enhanced IL-6 expression in primary microglia after μg/ml treatment. (b) Primary microglial release of IL-6 was robustly increased by 24 and 48 h μg/ml LPS treatment. (c) No substantial changes in IL-6 protein were observed in BV-2 cells following LPS treatment. (d) BV-2 cells increased release of IL-6 following all LPS treatments. (e) No change in IL-6 protein was observed in HAPI cells following LPS treatment. (f) No IL-6 was observed in HAPI cell media following any treatment. Results for western blot (a, c, e) are expressed as mean IL-6 immunoreactivity relative to β-actin and normalized to media control ± SEM. Results for ELISA experiments (b, d, f) are expressed as mean IL-6 (pg/ml) ± SEM. ND, non-detectable. * p<0.05, ** p<0.01 and *** p<0.001 compared to media control.